Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1a/b Dose Finding, Open-label Study to Evaluate Safety and Toxicity of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer

NCT05085990 is registered in ClinicalTrials.gov with Protara Therapeutics as lead sponsor.

NCT NCT05085990
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05085990 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1a/b Dose Finding, Open-label Study to Evaluate Safety and Toxicity of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer
Lead sponsor
Protara Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
May 8, 2023
Completion date
September 12, 2024
Enrollment
10 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

non-muscle invasive bladder cancer